43.50
-0.37 (-0.84%)
| Penutupan Terdahulu | 43.87 |
| Buka | 43.90 |
| Jumlah Dagangan | 142,886 |
| Purata Dagangan (3B) | 758,155 |
| Modal Pasaran | 4,016,977,152 |
| Harga / Jualan (P/S) | 7.35 |
| Harga / Buku (P/B) | 11.77 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Feb 2025 - 17 Feb 2025 |
| Margin Keuntungan | -106.93% |
| Margin Operasi (TTM) | -94.62% |
| EPS Cair (TTM) | -6.46 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 42.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 257.89% |
| Nisbah Semasa (MRQ) | 2.81 |
| Aliran Tunai Operasi (OCF TTM) | -418.59 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -231.16 M |
| Pulangan Atas Aset (ROA TTM) | -24.12% |
| Pulangan Atas Ekuiti (ROE TTM) | -289.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Ultragenyx Pharmaceutical Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.60 |
|
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.62% |
| % Dimiliki oleh Institusi | 97.44% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Alkeon Capital Management Llc | 30 Sep 2024 | 3,011,716 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 121.00 (Canaccord Genuity, 178.16%) | Beli |
| Median | 95.00 (118.39%) | |
| Rendah | 73.00 (TD Cowen, 67.82%) | Beli |
| Purata | 96.00 (120.69%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 48.15 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Dec 2024 | 95.00 (118.39%) | Beli | 43.50 |
| 06 Nov 2024 | 95.00 (118.39%) | Beli | 50.52 | |
| Wells Fargo | 20 Dec 2024 | 88.00 (102.30%) | Beli | 44.22 |
| JP Morgan | 21 Nov 2024 | 102.00 (134.48%) | Beli | 46.02 |
| Canaccord Genuity | 12 Nov 2024 | 121.00 (178.16%) | Beli | 47.84 |
| 06 Nov 2024 | 121.00 (178.16%) | Beli | 50.52 | |
| Cantor Fitzgerald | 06 Nov 2024 | 116.00 (166.67%) | Beli | 50.52 |
| 22 Oct 2024 | 116.00 (166.67%) | Beli | 54.79 | |
| RBC Capital | 06 Nov 2024 | 77.00 (77.01%) | Beli | 50.52 |
| 26 Sep 2024 | 77.00 (77.01%) | Beli | 55.22 | |
| TD Cowen | 21 Oct 2024 | 73.00 (67.82%) | Beli | 54.46 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |